tiprankstipranks
Zhejiang Taimei Medical Technology Co Ltd Class H (HK:2576)
:2576
Hong Kong Market
Want to see HK:2576 full AI Analyst Report?

Zhejiang Taimei Medical Technology Co Ltd Class H (2576) Price & Analysis

0 Followers

2576 Stock Chart & Stats

HK$4.20
-HK$0.14(-3.49%)
At close: 4:00 PM EST
HK$4.20
-HK$0.14(-3.49%)

Bulls Say, Bears Say

Bulls Say
Conservatively Financed Balance SheetLow debt (debt-to-equity ~3%–6%) gives the company durable financial flexibility to fund continued operating losses, invest in growth, and withstand shocks without immediate refinancing. This reduces insolvency risk and supports execution over the next several quarters.
Improving Gross MarginsA sustained increase in gross margin to ~42% signals structural improvement in pricing, product mix, or scale economics. If maintained, higher margins materially enhance profitability potential and reduce the revenue needed to reach break-even over the medium term.
Material Operational Improvement In 2025The 2025 rebound—large revenue pickup plus narrower losses—indicates the company is making operational progress. Persistent execution of these improvements would validate the business model’s scalability and meaningfully reduce funding pressure over the next 2–6 months.
Bears Say
Persistent Negative Cash FlowConsistent negative operating and free cash flow creates ongoing funding needs and elevates execution and dilution risk. Even with improving burn in 2025, sustained negative cash generation forces reliance on external capital or asset sales, constraining strategic optionality.
Still Loss-making At Operating LevelNegative operating profitability means core operations do not yet generate sustainable earnings. Until EBIT/EBITDA turns consistently positive, the company remains exposed to margin compression, limited internal funding for growth, and higher sensitivity to adverse demand shifts.
Revenue Volatility Despite ReboundA dramatic one-year revenue rebound following volatility indicates demand or execution variability. Such swings complicate planning, raise forecast risk, and mean the recent recovery may not persist without repeated evidence of stable customer acquisition and retention trends.

Zhejiang Taimei Medical Technology Co Ltd Class H News

2576 FAQ

What was Zhejiang Taimei Medical Technology Co Ltd Class H’s price range in the past 12 months?
Zhejiang Taimei Medical Technology Co Ltd Class H lowest stock price was HK$3.31 and its highest was HK$6.20 in the past 12 months.
    What is Zhejiang Taimei Medical Technology Co Ltd Class H’s market cap?
    Zhejiang Taimei Medical Technology Co Ltd Class H’s market cap is HK$3.16B.
      When is Zhejiang Taimei Medical Technology Co Ltd Class H’s upcoming earnings report date?
      The company’s upcoming earnings report date is not yet available.
      How were Zhejiang Taimei Medical Technology Co Ltd Class H’s earnings last quarter?
      Currently, no data Available
      Is Zhejiang Taimei Medical Technology Co Ltd Class H overvalued?
      According to Wall Street analysts Zhejiang Taimei Medical Technology Co Ltd Class H’s price is currently Overvalued. Get more investment ideas with TipRanks Premium
        Does Zhejiang Taimei Medical Technology Co Ltd Class H pay dividends?
        Zhejiang Taimei Medical Technology Co Ltd Class H does not currently pay dividends.
        What is Zhejiang Taimei Medical Technology Co Ltd Class H’s EPS estimate?
        Zhejiang Taimei Medical Technology Co Ltd Class H’s EPS estimate for its next earnings report is not yet available.
        How many shares outstanding does Zhejiang Taimei Medical Technology Co Ltd Class H have?
        Zhejiang Taimei Medical Technology Co Ltd Class H has 200,592,530 shares outstanding.
          What happened to Zhejiang Taimei Medical Technology Co Ltd Class H’s price movement after its last earnings report?
          Currently, no data Available
          Which hedge fund is a major shareholder of Zhejiang Taimei Medical Technology Co Ltd Class H?
          Currently, no hedge funds are holding shares in HK:2576
          What is the TipRanks Smart Score and how is it calculated?
          Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

            Zhejiang Taimei Medical Technology Co Ltd Class H Stock Smart Score

            Company Description

            Zhejiang Taimei Medical Technology Co Ltd Class H

            Zhejiang Taimei Medical Technology Co., Ltd., established in 2013 and based in Jiaxing, China, specializes in delivering sophisticated digital operational platforms specifically designed for the biopharmaceutical industry across the country. The company's core offering is TrialOS, a comprehensive digital collaboration platform that seamlessly integrates all participants throughout the drug development and research lifecycle. This ecosystem effectively links hospitals, pharmaceutical firms, external service providers, regulatory bodies, and patients, among other key industry stakeholders. Its extensive portfolio of software solutions caters to various critical aspects of clinical research and drug development. For streamlining clinical trial operations, Taimei Medical provides tools like eCooperate, which optimizes management systems and leverages big data for informed decision-making. Other related offerings include eArchives for managing master files, eCollect for electronic data capture, eCollege for training administration, eQuality for electronic audit processes, and eBalance for interactive web-based responses. Innovations such as eVisit Patient Reported Outcomes are designed to enhance patient data input and accuracy, while eTime supports project time management, and eImage facilitates medical image interpretation. Furthermore, the company supplies specialized software tailored for hospitals and Good Clinical Practice (GCP) sites. These include eTrial for managing Phase I wards, eSite and NomenCTMS for comprehensive clinical trial management at study sites, and intelligent platforms like GCP-X and Intelligent Investigator. Solutions such as eScreening assist with subject information management and deduplication, while IIT-EDC and the Investigator-Initiated Clinical Trial Management System support investigator-initiated studies and their associated data management. In the crucial domain of drug safety, the company offers robust pharmacovigilance software solutions. This includes both global and intelligent eSafety systems, alongside the SAE Manager for efficient communication and management of critical safety data during clinical trials. Complementing these, Zhejiang Taimei also develops marketing software and a variety of other digital innovation solutions.

            Zhejiang Taimei Medical Technology Co Ltd Class H (2576) Earnings & Revenues

            Similar Stocks
            Company
            Price & Change
            Follow
            Human Health Holdings Ltd.
            Vincent Medical Holdings Limited
            Tycoon Group Holdings Limited
            China Tian Yuan Healthcare Group Limited
            UMP Healthcare Holdings Limited
            Popular Stocks